Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide

Alessandra Soriano 1*, Marco Soriano 2, Gerard Espinosa 3, Raffaele Manna 4, Giacomo Emmi 5, Luca Cantarini 6 and José Hernández-Rodríguez 3

Monogenic autoinflammatory diseases are rare conditions caused by genetic abnormalities affecting the innate immunity. Previous therapeutic strategies had been mainly based on results from retrospective studies and physicians’ experience. However, during the last years, the significant improvement in their genetic and pathogenic knowledge has been accompanied by a remarkable progress in their management. The relatively recent identification of the inflammasome as the crucial pathogenic mechanism causing an aberrant production of interleukin 1β (IL-1β) in the most frequent monogenic autoinflammatory diseases led to the introduction of anti–IL-1 agents and other biologic drugs as part of the previously limited therapeutic armamentarium available. Advances in the treatment of autoinflammatory diseases have been favored by the use of new biologic agents and the performance of a notable number of randomized clinical trials exploring the efficacy and safety of these agents. Clinical trials have contributed to increase the level of evidence and provided more robust therapeutic recommendations. This review analyzes the treatment of the most frequent monogenic autoinflammatory diseases, namely, familial Mediterranean fever, tumor necrosis factor–associated periodic fever syndrome, hyperimmunoglobulin D syndrome/mevalonate kinase deficiency, and cryopyrin-associated periodic syndromes, together with periodic fever with aphthous stomatitis, pharyngitis, and cervical adenitis syndrome, which is the most common polygenic autoinflammatory disease in children, also occurring in adult patients. Finally, based on the available expert consensus recommendations and the highest level of evidence of the published studies, a practical evidence-based guideline for the treatment of these autoinflammatory diseases is proposed.

Keywords: monogenic autoinflammatory diseases, PFAPA syndrome, colchicine, anakinra, canakinumab, anti-TNF agents, tocilizumab, Janus kinase (JAK) inhibitors
INTRODUCTION

Over the past 20 years, pathogenic insights into the mechanisms of autoinflammation completely changed treatment and prognosis of many inherited autoinflammatory diseases, also known as “hereditary periodic fever syndromes,” a group of rare diseases characterized by difficult diagnostic and therapeutic approaches. The most extensively studied and better pathogenically defined monogenic autoinflammatory conditions have been familial Mediterranean fever (FMF), tumor necrosis factor (TNF) receptor–associated periodic fever syndrome (TRAPS), hyperimmunoglobulin D syndrome/mevalonate kinase deficiency (HIDS/MKD), and cryopyrin-associated periodic syndromes (CAPS), which comprise three disorders with the same genetic background, and different phenotypes and outcomes. The CAPS spectrum includes familial cold autoinflammatory syndrome (FCAS), the mildest form; Muckle-Wells syndrome (MWS), the intermediate presentation; and chronic infantile neurological, cutaneous, and articular syndrome (CINCA) or neonatal-onset multisystem inflammatory disorder (NOMID), the most severe disease (1).

Until the late 1990s, traditional drugs, such as colchicine and glucocorticoids, had been used to treat autoinflammatory diseases. The pathogenic and therapeutic revolution started when NLRP3, one of the NOD-like receptors (NLRs) and part of the NLRP3 inflammasome, was discovered as the main actor in the activation of caspase 1 and the subsequent production of active interleukin 1β (IL-1β) (2). Mutations of genes involved in the inflammasome function or its related pathways were then identified as responsible for most of the monogenic autoinflammatory disorders recognized so far, also known as inflammasomopathies (3).

The discovery of the aberrant production of IL-1β as the final cause of all inflammasomopathies led to the introduction of anti–IL-1 agents and other biologic drugs to the very limited therapeutic armamentarium available for such diseases until then (4). In addition, the more recent knowledge of other autoinflammatory mechanisms, such as the activation of nuclear factor κB (NF-κB) and type I interferon (IFN) pathways, also provided new therapeutic options, such as anti-TNF and Janus kinase (JAK) inhibitors agents, directed to the specific blockade of cytokines and molecules involved in these novel inflammatory mechanisms (5–9).

Because monogenic autoinflammatory diseases are rare conditions, therapeutic strategies had been mainly based on results from retrospective studies and expert physicians’ experience. Nevertheless, during the last years, the vast improvement in their genetic and pathogenic knowledge has been accompanied by a great effort in improving their management. In this sense, a remarkable number of randomized clinical trials exploring the efficacy and safety of new biologic agents in autoinflammatory diseases have been conducted, and therefore, therapeutic recommendations can be based now on higher evidence levels.

OBJECTIVES AND METHODOLOGY OF THE REVIEW

This review intends to analyze the use of conventional and biologic agents in the most prevalent monogenic autoinflammatory diseases (FMF, TRAPS, HIDS/MKD, and CAPS) and periodic fever syndrome, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome. Although PFAPA syndrome is a polygenic or multifactorial disease with an unidentified genetic background, its treatment is reviewed because PFAPA syndrome is the most frequent autoinflammatory condition in childhood and has to be frequently considered part of the differential diagnosis of some monogenic disorders in children and adults (10).

Evidence-based recommendations for the management of FMF, TRAPS, HIDS/MKD, and CAPS have been provided from previous consensus studies using the European League Against Rheumatism (EULAR) standard operating procedures for developing best practice (Table 1) (11, 12), such as the EULAR recommendations for the management of FMF (13), and the European SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) recommendations for the management of CAPS, TRAPS, and MKD (14). For all the autoinflammatory diseases, results of new clinical trials, international multicenter collaborative studies and registries, and retrospective data preferably from referral centers, have also been used to generate levels of evidence. The most relevant international multicenter initiatives and registries include the PRINTO Registry (a secured web-based registry hosted at the Pediatric Rheumatology International Trial Organization website - PRINTO, http://www.printo.it) and EUROFEVER Registry (an international registry for autoinflammatory diseases, https://www.printo.it/eurofever/) (15).

Because, by definition, the strength of recommendation has to be based on a combination of data extracted from systematic literature review (providing levels of evidence) and consensus expert opinion (providing homogeneous and measurable information to generate the recommendations), in those conditions or situations for which any new therapeutic information has been reported but no opinion of the experts has been issued yet, only the level of evidence is mentioned (11, 12).

TRADITIONAL DRUGS

Colchicine

Colchicine is an alkaloid extracted from two plants of the Lily family: Colchicum autumnale and Gloriosa superba. Historically, the therapeutic role of colchicine was for the first time raised for the treatment of gout in the sixth century (16). More recently, colchicine use has been extended to other diseases such as primary biliary cirrhosis, Behçet disease, recurrent pericarditis, alcohol induced hepatitis, psoriasis, scleroderma, Sweet syndrome, amyloidosis, sarcoidosis and, in lesser extent, to inflammatory disorders prone to fibrosis (17–19).

In 1972, the efficacy of colchicine was first described in five FMF patients who experienced a dramatic reduction of
TABLE 1 | Categorization of the level of clinical evidence and strength of recommendation based on the EULAR standardized operating procedures for EULAR-endorsed recommendations (11, 12).

| Category | Evidence from |
|----------|---------------|
| **LEVELS OF EVIDENCE** | |
| 1A | Meta-analysis of randomized controlled trials |
| 1B | At least one randomized controlled trial |
| 2A | At least one controlled study without randomization |
| 2B | At least one type of quasi-experimental study |
| 3 | Descriptive studies, such as comparative studies, correlation studies, or case-control studies |
| 4 | Expert committee reports or opinions and/or clinical experience of respected authorities |

| Grade | Directly based on |
|-------|------------------|
| **STRENGTH OF RECOMMENDATION** | |
| A | Category 1 evidence |
| B | Category 2 evidence or extrapolated recommendation from category 2 evidence |
| C | Category 3 evidence or extrapolated recommendation from category 1 or 2 evidence |
| D | Category 4 evidence or extrapolated recommendation from category 2 or 3 evidence |

the number of attacks (20). Since then, colchicine has become the basis of FMF treatment, and later on, several clinical trials definitively established its efficacy in preventing attacks and developing amyloidosis (21–23).

Colchicine was officially approved in 2009 by the US Food and Drug Administration (FDA) for the acute flares of gout and FMF, as a single-ingredient oral formulation (Colcrys®) (24). Nowadays, according to 2016 EULAR recommendations for the management of FMF, colchicine represents the first-line treatment in FMF, with a level of evidence 1B and grade of recommendation A (13).

Among other biological functions, colchicine has anti-inflammatory properties based on the inhibition of leukocyte chemotaxis, which is caused by its interaction with tubulin and the resulting dysfunction of microtubules. Microtubules, composed by α- and β-tubulin heterodimers, are involved in cell division, signal transduction, migration, secretion, and regulation of gene expression (25). Colchicine has the ability to bind in a poorly reversible manner to soluble non-polymerized tubulin in the cells, with the formation of a tubulin–colchicine complex (26, 27), and the subsequent movement inhibition of intracellular granules (28).

The predominant effect of colchicine on leukocytes, and more specific on granulocytes, has been correlated with the high concentrations of the drug in neutrophils compared to lymphocytes and monocytes. In this regard, defects in the efflux pumps with low activity of the P-glycoprotein 1 (PGY-1) efflux pump of granulocytes might explain the accumulation of colchicine in their cytoplasm (29, 30).

Other anti-inflammatory effects of colchicine include the reduction of TNF-α production by macrophages and TNF-α receptors on endothelial cells and the abrogation of neutrophil binding to adhesion molecules on vascular endothelium. Colchicine also decreases phospholipase A2 activity, release of lysosomal enzymes, and phagocytosis (31–33).

After the discovery of the MEFV gene as the gene encoding for pyrin and responsible for FMF, MEFV was found fully expressed in neutrophils, and some authors evidenced a colchicine-related cytosolic modulation of pyrin expression (34–36). Finally, colchicine has been shown to suppress the activation of caspase 1, the enzymatic component of NLRP3 inflammasome, with the subsequent inability to convert pro–IL-1β to active IL-1β (37).

Pharmacokinetic properties of colchicine include a narrow therapeutic range because the half-life after oral ingestion ranges between 7 and 9 h. The drug is absorbed in the jejunum and ileum and is metabolized in the liver by the cytochrome P (CYP) 450 3A4 and PGY-1. It is finally excreted mainly by the biliary, intestinal, and renal systems. Colchicine use in pregnant or nursing patients is considered relatively safe as long as hepatic and renal functions are intact. In this regard, because colchicine is metabolized via CYP3A4, its concomitant administration with agents that inhibit this isoenzyme (e.g., macrolide antibiotics, azole antifungals, statins) may produce elevated colchicine plasma concentrations, resulting in severe, and sometimes fatal complications. Colchicine intoxication may be also induced in patients with renal and/or liver disorders (38, 39).

Colchicine in Autoinflammatory Diseases

**Familial Mediterranean Fever**

Therapeutic doses of colchicine to treat FMF should be adjusted to the body weight, with a mean optimal dose of 0.03 ± 0.02 mg/kg per day. Total doses usually range from 0.5 to 2 mg/d in children and from 1 to 3 mg/d in adults (40, 41). Colchicine usually reduces severity, duration, and frequency of the attacks in the majority of FMF patients. Among them, ~30–40% of individuals experience a partial response (42). After ruling out any colchicine-associated gastrointestinal intolerance, other adverse effect, or poor patient compliance, only 5–10% of FMF cases can be finally considered colchicine-resistant FMF (crFMF) patients (15, 43).

Intravenous colchicine has shown efficacy in some patients unresponsive or with partial response to the oral formulation (43–44). An adjunctive weekly infusion of (1 mg) colchicine in FMF patients with frequent attacks despite a maximum tolerated oral dosage of 2–3 mg/d was associated with 50% reduction in frequency of attacks after 6 months (45). However, because of the potential risk of toxicity, intravenous colchicine is currently not recommended in FMF patients unresponsive to the oral formulation.

**Other Autoinflammatory Diseases**

Colchicine has not demonstrated effectiveness in HIDS/MKD and CAPS (14, 15). However, it has shown to be somehow effective in TRAPS and PFAPA syndrome. In the Eurofever Registry, colchicine was used in 39 TRAPS patients, with complete and partial response in 3 (8%) and 18 (46%) individuals, respectively (15). In a recent study of 24 patients with TRAPS,
colchicine resulted to be of some help in 71% of cases, with a complete response in 12.5% of them. No differences in colchicine response were observed with regard to age at disease onset (pediatric vs. adult), type of variant (low vs. high penetrance), and colchicine daily doses (1 mg vs. higher doses) (46). In 303 PFAPA patients from a tertiary Turkish center, colchicine was used as regular prophylactic treatment with high rate of response in terms of reduction of the frequency of episodes. Interestingly, heterozygous mutations in the MEFV gene were found in 25% of PFAPA subjects, who obtained even better results in terms of reduction of attacks. The potential modifer role of MEFV mutations in PFAPA patients seems associated with attenuated disease severity and higher response rate to colchicine compared to non-carriers of MEFV variants (47–49).

Non-steroidal Anti-inflammatory Drugs

The main therapeutic effects of non-steroidal anti-inflammatory drugs (NSAIDs) are determined by the inhibition of cyclooxygenases, enzymes that convert arachidonic acid in prostaglandins, and thromboxanes. Some of these eicosanoids participate in different pathways involved in the inflammatory response. However, because NSAIDs do not inhibit the biosynthetic cascade originating arachidonic acid, these drugs do not usually influence the underlying cause of the disease.

NSAIDs in Autoinflammatory Diseases

NSAIDs have been used in monogenic autoinflammatory diseases as symptomatic treatment, alone or in addition to the baseline therapy. Although a complete response has been reported in a minority of patients with autoinflammatory conditions in the Eurofever Registry (8% of FMF and TRAPS, 13% of HIDS/MKD, 6% of CAPS, and 4% of PFAPA patients), NSAIDs, alone or in combination with glucocorticoids, appear to be of some help in 70–80% of all cases (15).

In some FMF patients with exertional leg pain and protracted febrile myalgia, similarly to glucocorticoids, NSAIDs seem to be also effective (50). Protracted febrile myalgia is a condition characterized by prolonged episodes of muscle pain affecting limbs with marked systemic inflammatory response in the absence of rhabdomyolysis. The EULAR recommendations for treating this complication with NSAIDs have a level of evidence 2B and grade of recommendation C (13).

Patients with TRAPS associated with R92Q mutations have been reported to respond better to the combination of colchicine and NSAIDs than those carrying clearly pathogenic TNFRSF1A mutations (15, 51). However, in TRAPS, HIDS/MKD, and CAPS patients, the use of NSAIDs as pain relievers during inflammatory attacks is recommended with a level of evidence 3 and strength of recommendation D (for TRAPS) and C (for HIDS/MKD, CAPS, and PFAPA syndrome) (14, 15).

Glucocorticoids

Glucocorticoids suppress the production and effects of several proinflammatory mediators, induce the inhibition of leukocytes migration to the inflammatory foci, and interfere with the function of fibroblasts and endothelial cells, thereby exerting a powerful anti-inflammatory action, both on acute manifestations (i.e., pain, edema) and on late inflammatory stages (including reparative processes, such as cell proliferation and fibrosis). Glucocorticoids bind to a specific intracytoplasmic receptor, a ligand-activated transcription factor with both positive and negative effects on the regulation of gene expression. Consequently, the activated glucocorticoid receptor–glucocorticoid complex up-regulates the expression of anti-inflammatory proteins and suppresses the transcription of proinflammatory cytokines and chemokines by blocking the NF-κB signaling pathway (52).

Glucocorticoids in Autoinflammatory Diseases

Familial Mediterranean Fever

In FMF patients, when colchicine becomes insufficient to control the disease activity, glucocorticoids (always in combination with colchicine) have shown positive effects with variable response in 83% of the 47 cases recruited from the Eurofever Registry (15). The use of intravenous methylprednisolone (40 mg) on demand has also demonstrated efficacy in decreasing fever and abdominal and pleuritic pain during attacks in a study of 31 FMF patients (53).

FMF patients with protracted febrile myalgia may be controlled with intravenous and/or oral administration of high-dose glucocorticoids (54). In fact, glucocorticoids have been recommended for treating this complication with a level of evidence 2B and grade of recommendation C (13). A recent study on eight FMF patients with protracted febrile myalgia has shown good response with the use of intravenous methylprednisolone pulses, at a dose of 10 mg/kg per day, for 3 days, followed by oral glucocorticoids, at initial doses of 1–2 mg/kg and gradual tapering down over 6 weeks (55). A small comparative study on 15 FMF patients with protracted febrile myalgia suggested similar efficacy of oral glucocorticoids and NSAIDs (50).

Tumor Necrosis Factor Receptor–Associated Periodic Fever Syndrome

In TRAPS patients, prednisone (or equivalent) may be useful on demand, administered during the attacks at a dose of 1 mg/kg per day, usually with rapid tapering and cessation in the following days (51, 56, 57). In the Eurofever Registry, short-term glucocorticoids, with or without concomitant NSAIDs, were considered effective for controlling inflammatory attacks in 91% of TRAPS patients, with complete response in 41% of them (15). Glucocorticoids do not seem to have any significant effect in preventing amyloidosis, and its intermittent use does not reduce either the frequency of attacks or subclinical inflammation between them. Glucocorticoids in TRAPS are recommended either as short-term courses or as maintenance treatment with a level of evidence 3 and strength of recommendation C (14).

As in other monogenic autoinflammatory disorders, some TRAPS patients may require long-term glucocorticoid therapy. In these glucocorticoid-dependent situations, a biological agent is often warranted in order to avoid steroid side effects. Indeed, almost 80% of TRAPS patients initially treated with glucocorticoids may finally receive biologic agents as maintenance therapy to control symptoms (14, 58).
**Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency**

Similarly to TRAPS patients, in HIDS/MKD, high-dose glucocorticoids may be useful during the attacks with some benefit in 73% of cases. However, complete improvement is achieved by only 9% of patients, and glucocorticoids do not decrease neither the intensity nor the frequency of the acute episodes (15). Short-term glucocorticoids, with or without NSAIDs, may be effective for alleviating inflammatory attacks and are recommended with a level of evidence 3 and strength of recommendation C (14).

**Cryopyrin-Associated Periodic Syndromes**

In CAPS patients, glucocorticoids, mostly used on demand, resulted in some benefit in 80% of patients included in the Eurofever Registry. However, glucocorticoids do not control the underlying inflammatory process or decrease the frequency of the attacks (15, 59). Anyway, for symptomatic adjunctive therapy, short courses of NSAIDs and glucocorticoids may be used, with a level of evidence 3 and strength of recommendation C (14). However, they should not be used for primary maintenance therapy (level of evidence 4 and grade of recommendation D) (14).

**PFAPA Syndrome**

Glucocorticoids are the treatment of choice in PFAPA syndrome, because their prompt administration is able to discontinue the attacks rapidly and completely in the majority of patients. Such dramatic response is usually considered a peculiar diagnostic feature in pediatric and adult patients (15, 60–63). The conventional dosage from 0.5 to 2 mg/kg of prednisone (or equivalent) in a single dose at the time of fever onset has been proved useful in a randomized clinical trial (64), and therefore, glucocorticoids can be recommended in PFAPA patients with a level of evidence 2B (15). However, additional doses of glucocorticoids may be occasionally necessary. Their use does not prevent further attacks and may even be associated with an increased frequency of the attacks in 25–50% of cases (15, 60).

Of note, the evidence for the effectiveness of tonsillectomy in children with PFAPA syndrome is based on a systematic review that included two small randomized controlled trials studying the effects of tonsillectomy compared to no surgery. Tonsillectomy was associated with immediate and complete clinical resolution and significant reduction in the frequency and severity of symptoms (65). Although these results have to be interpreted considering the clinical severity, the previous response to a single dose of prednisone, and the surgical risk in every individual situation, tonsillectomy as a therapy for PFAPA syndrome can be recommended with a level of evidence 1A (15).

**Other Conventional Agents**

**Thalidomide**

Thalidomide exerts its immunomodulatory and anti-inflammatory actions through inhibiting TNF-α and IFN-γ synthesis, leukocyte chemotaxis, and angiogenesis. Teratogenicity and polyneuropathy are known as the most feared thalidomide-related serious adverse events. Thalidomide is an accepted treatment for dermatological diseases (such as leprosy erythema nodosum, severe mucosal ulcers, cutaneous lupus erythematosus, and chronic graft-vs.-host disease), refractory multiple myeloma, and other systemic autoimmune or inflammatory conditions. Evidence on the efficacy of thalidomide in autoinflammatory diseases is limited to sporadic case reports and series. In three crFMF patients treated with thalidomide in addition to colchicine, the combination did not show clear benefit (66). Similarly, thalidomide failed to demonstrate any biological or clinical effect in six patients with HIDS/MKD (67).

**Dapsone**

Dapsone is an antibacterial sulfonamide drug with anti-inflammatory properties due to the inhibition of function and chemotaxis of neutrophils and blockade of the inflammatory effects of multiple prostaglandins and leukotrienes. Dapsone is currently used for the treatment of different infectious and immune-mediated systemic and dermatologic conditions (68). In monogenic autoinflammatory diseases, dapsone has been used in a case series of 10 crFMF patients with control of attacks in half of them. The authors postulated that dapsone might be considered as an alternative therapy in selected FMF cases not responding to colchicine (68).

**Interferon α**

The use of IFN-α in patients with FMF resistant to colchicine has been reported with controversial results. While in several crFMF cases IFN-α seemed to induce a marked decrease in both severity and frequency of the attacks, alone or in combination with colchicine (69–72), a double-blind randomized clinical trial of 22 FMF patients comparing IFN-α with placebo (without concomitant colchicine) did not demonstrate clear efficacy of IFN-α in reducing severity of attacks or inflammatory markers (73).

**Other Drugs**

Other anti-inflammatory, immune-modulatory, or immunosuppressive agents, such as azathioprine, methotrexate, cyclosporine, leflunomide, mycophenolate mofetil, sulfasalazine, statins, cimetidine, and antihistamines, have been historically used in monogenic autoinflammatory diseases mostly with unclear or unsatisfactory results (15, 51).

**BIOLOGIC AGENTS**

**Interleukin 1 Blockers**

It is well-known that IL-1 production has strong impact on initiation and maintenance of inflammatory process. Both IL-1α and IL-1β bind to the IL-1 receptor type, which is expressed by nearly every human cell and is responsible for triggering the cascade of inflammatory processes (74). IL-1 inhibitory molecule was first described over 30 years ago in the urine from patients with fever and monocytic leukemia (75, 76). This molecule was later cloned and identified as IL-1 receptor antagonist (IL-1Ra) (77), and subsequently, it was hypothesized that the inhibition of IL-1 with IL-1Ra could be a potential therapeutic option for treating inflammatory diseases (78).
TABLE 2 | Anti-IL-1 agents, types of studies supporting the maximum evidence level for their use, and common pediatric and adult doses given in the main monogenic autoinflammatory diseases (crFMF, TRAPS, HIDS/MKD, and CAPS) and PFAPA syndrome.

| Anti-IL-1 agent | Disease | Type of study | EMA/FDA approval | Doses (children) | Doses (adults) | References |
|----------------|---------|---------------|------------------|-----------------|---------------|------------|
| Anakinra       | crFMF   | RCT, RCS      | No/No            | 50–300 mg/day   | 50–100 mg/day | (80, 81)   |
|                | TRAPS   | OLS, CS       | No/No            | 1.5 mg/kg/day   | 100 mg/day    | (82, 83)   |
|                | HIDS/MKD| OLS           | No / No          | 1 mg/kg/day     | 100 mg/day*   | (84)       |
|                | CAPS    | OLS, RCS, CS  | Yes/Yes**        | 1–1.5 mg/kg/day,| 100 mg/day,   | (85–92)    |
|                |         |               |                  | 1–2 mg/kg/day,  | 1–2 mg/kg/day,|            |
|                |         |               |                  | 1.5–8 mg/kg/day | 1–2 mg/kg/day,|            |
|                |         |               |                  |                 | 1.5–8 mg/kg/day|            |
|                | PFAPA   | CS, CR        | No/No            | 1 mg/kg/day     | 100 mg/day*   | (83, 94)   |
| Canakinumab    | crFMF   | RCT, OLS      | Yes/Yes          | 2 mg/Kg q4w or q8w | 150–300 mg q4w or q8w | (95–97) |
|                | TRAPS   | RCT, OLS      | Yes/Yes          | 2 mg/Kg q4w or q8w | 150–300 mg q4w or q8w | (95, 98) |
|                | HIDS/MKD| RCT, OLS      | Yes/Yes          | 2 mg/Kg q4w or q8w | 150–300 mg q4w or q8w | (95, 99) |
|                | CAPS    | RCT, OLS      | Yes/Yes          | 2–10 mg/Kg q4w or q8w | 150–300 mg q4w or q8w | (100–104) |
|                | PFAPA   | CR            | No/No            | 2 mg/kg q8w     | 150 mg q8w    | (105, 106) |
| Rilonacept     | crFMF   | RCT           | No/No            | 2.2 mg/Kg qw    | 160 mg qw     | (107)      |
|                | CAPS    | RCT, OLS      | No/No            | 4.4 mg/Kg followed by 2.2 mg/Kg qw | 320 mg followed by 160 mg qw | (108, 109) |

*In some cases, on demand administration at the beginning of the febrile episode may also be used.
**Only for CINCA/NOMID cases.

With regard to inflammasome-mediated autoinflammatory diseases, such as FMF, TRAPS, HIDS/MKD, and CAPS, IL-1 blockade has become the most specific and useful treatment, as first-line therapy or when previous conventional anti-inflammatory or immunosuppressive agents are not useful. Although several IL-1 blockers are currently under development (79), the three biologic agents targeting IL-1 with special interest in autoinflammatory diseases, commercially available nowadays, are anakinra, canakinumab, and rilonacept. Table 2 illustrates the most relevant studies supporting the maximum evidence level for the use of IL-1 blockers in the main monogenic autoinflammatory diseases (crFMF, TRAPS, HIDS/MKD, and CAPS) and PFAPA syndrome and includes the doses used in pediatric and adult patients.

Anakinra

Anakinra is a recombinant non-glycosylated form of the human IL-1 receptor antagonist (rhIL-1Ra) that binds to IL-1 receptor type 1 (IL-1RI) and acts as competitive inhibitor with IL-1α and IL-1β, in a way that mimics the activity of endogenous IL-1Ra (110). Anakinra has been approved by the FDA and European Medicines Agency (EMA) for rheumatoid arthritis and by the EMA for the treatment of Still disease, including systemic juvenile idiopathic arthritis and adult-onset Still disease. In 2012, anakinra was approved for the treatment of CINCA/NOMID in the United States. In the European Union, anakinra was approved by the EMA for all types of CAPS in 2013.

The recommended initial dose of anakinra is 100 mg/d subcutaneously in adults and 0.5–2 mg/kg per day in children, who may require increasing dosage up to 5–8 mg/kg per day to maintain remission. The need of higher requirements of anakinra in pediatric patients might be related to pharmacokinetics of the drug whose effective steady-state concentration in young children seems to be higher than in adults (14, 111). Anakinra terminal half-life ranges from 4 to 6 h, and ~80% of the drug is excreted by renal clearance (112). Consequently, the mean plasma clearance of the drug strongly depends on normal kidney function, and anakinra removal from plasma is minimally feasible through dialysis (113).

An animal study showed that up to two-thirds of serum IL-1Ra are able to cross blood–brain barrier. On clinical grounds, anakinra administration has determined improvement of memory and cognitive functions in CAPS patients (85, 114).

Safety data on anakinra comes from rheumatoid arthritis randomized controlled trials and long-term observational studies, in which good safety profiles have been observed with no increase of opportunistic infections or malignancies (141, 142). Data from the British Society of Rheumatology Biologic Register reported higher rates of serious infections of the skin and respiratory tract in subjects with more severe disease and higher exposure to glucocorticoids (143). The increased susceptibility to respiratory infections in patients treated with anti–IL-1 might be explained by the fact that IL-1β seems to play a role in the resistance to Streptococcus pneumoniae infection (144). Although the most frequent adverse event by far of anakinra is the injection site skin reaction, which is observed in up to 70% of patients, this local reaction tends to decline over time without the need of treatment discontinuation (145). Anakinra use during...
Canakinumab

Canakinumab is a fully humanized IgG1 monoclonal antibody that acts specifically against IL-1β. In 2009, canakinumab received the FDA approval for CAPS treatment, specifically for FCAS and MWS, and EMA approval for children older than 2 years and adults with all forms of CAPS. More recently, in 2016, the FDA and EMA approved canakinumab for the treatment of crFMF, TRAPS, and MKD, based on the results of the phase 3 Canakinumab Pivotal Umbrella Study in Three Hereditary Periodic Fevers (CLUSTER) trial (95). Additional indications of canakinumab include systemic juvenile idiopathic arthritis (by the FDA) and Still disease (systemic juvenile idiopathic arthritis and adult-onset Still disease) and gouty arthritis (by the EMA).

Given its long half-life of 26 days, canakinumab administration is recommended subcutaneously at 2–4 mg/kg in children and at a minimal dose of 150 mg in adults, every 4–8 weeks in both age groups. Patients with more severe phenotypes may require dose escalation. For instance, patients with CINCA/NOMID (the most severe CAPS phenotype) may require up to 8 mg/kg dosage every 4 weeks to control symptoms (100, 101). Similarly, in crFMF, TRAPS, and MKD patients, the recommended starting dose is usually 150 mg or 2 mg/kg (in children with body weight between 7.5 and 49 kg) every 4 weeks, with the possibility to increase up to 300 mg every 4 weeks (or 4 mg/kg in children), which is more often required by MKD patients (95).

Its penetrance of the blood–brain barrier seems incomplete because canakinumab does not normalize intrathecal inflammatory markers, as demonstrated in two case series of CINCA/NOMID patients (149, 150). Renal function does not influence the pharmacokinetics of canakinumab (151). Data on pregnancy and breastfeeding are still scarce. However, seven of eight pregnancies of patients on canakinumab were reported uneventful, and no developmental abnormalities were reported in four breastfed infants while mothers were on canakinumab treatment (152).

Mild infections, involving mostly the urinary tract and upper airway, represent the most frequent canakinumab-associated adverse events. However, serious infections have been reported in 5.4/100 patients-years in 285 patients included in the long-term CAPS registry (153) and in 7.4/100 patients-years of FMF, TRAPS, and MKD patients treated with higher doses of canakinumab in the CLUSTER trial (95).

Additional data on safety can be extrapolated from the randomized, double-blind, placebo controlled trial of canakinumab in patients with atherosclerotic disease, with more than 10,000 individuals and ~30% of them receiving placebo (154). Neutropenia and thrombocytopenia were observed in the treatment group, with more deaths attributed to infections or sepsis, however, with no statistically significant differences in the overall rates of adverse events compared with placebo (154).

Rilonacept

Rilonacept is a dimeric fusion glycoprotein consisting of the Fc portion of human IgG1 and the human IL-1 receptor extracellular domains that binds IL-1α and IL-1β. In 2008, rilonacept was the first agent approved by the FDA for the treatment of FCAS and MWS in patients older than 12 years, based on two sequential phase III clinical studies, which demonstrated rilonacept safety and effectiveness in adult patients with CAPS (108). Rilonacept obtained a marketing authorization only in the United States.

Initial dose in adults is recommended at 320 mg subcutaneously, followed by a weekly dose of 160 mg. In children older than 11 years and adolescents, the dose has to be adjusted at 4.4 mg/kg (maximum of 320 mg) and then 2.2 mg/kg (maximum of 160 mg) once weekly. The circulating half-life may vary from 6 to 9 days (155, 156). Being a large molecule, it is expected not to cross the blood–brain barrier and to be cleared primarily by the reticuloendothelial system rather than by the kidney. Therefore, a dose adjustment in patients with renal disease is not required (157).

Injection site reactions, headache, and upper respiratory tract and urinary infections have been described as the most common adverse events in CAPS patients treated with rilonacept (109). Data from studies and trials on gout and gouty arthritis suggest also that several laboratory changes may occur, including transient neutropenia and a small increase in liver transaminases, triglycerides, and creatine phosphokinase (158).

IL-1 Blockers in Autoinflammatory Diseases

Familial Mediterranean Fever

IL-1 blockade with anakinra is currently recommended for FMF in case of true colchicine resistance, with a level of evidence 2B and strength of recommendation B, and as an optional treatment for protracted febrile myalgia, with a level of agreement 2B and grade of recommendation C (13).

Although in 2011 the Eurofever Registry included only three FMF patients treated with anakinra with complete response (15), a 2013 literature review identified 30 FMF cases resistant or intolerant to colchicine treated with anakinra, and four with canakinumab, with good clinical and laboratory outcomes (110). A 2015 systematic review reported 64 patients treated with anakinra and 40 with canakinumab. A complete response without attacks occurred in 76.5 and 67.5% of patients on anakinra and canakinumab, respectively. In patients with established type AA amyloidosis, both anti–IL-1 agents demonstrated to reverse proteinuria (159). Anakinra has been administered on demand with efficacy to some selected crFMF patients, mainly those with prominent prodromal manifestations or recognizable triggers of the attacks (160).

Ben-Zvi et al. (80) enrolled 25 adult patients with crFMF in the first double-blind randomized placebo-controlled trial, aiming to assess efficacy and safety of anakinra at a dose of 100 mg/d during 4 months of treatment. Adult FMF patients experiencing at least one attack per month despite the maximum tolerated dose of colchicine (up to 3 mg/d) were enrolled. Patients treated with anakinra had an attack rate of 1.7 per month, whereas those receiving placebo suffered 3.5 attacks per month.
In addition, anakinra was associated with better quality of life, and no differences in the development of adverse effects were found. Interestingly, the best results with anakinra were observed in terms of amelioration of joint manifestations (80). In a Turkish multicenter retrospective study of 172 crFMF patients, in whom 151 were treated with anakinra and 21 with canakinumab, both drugs reduced the yearly attack frequency from 16.8 to 2.4 (p < 0.001). Forty-two percent of crFMF patients were attack-free, and proteinuria was significantly reduced in those patients with amyloidosis (81).

Canakinumab has proved effective in several retrospective FMF reviews (161–163) and two open-label phase II studies with nine and seven crFMF patients (96, 97). Both phase II trials established the efficacy of canakinumab in reducing the frequency of FMF attacks and maintaining low levels of acute phase reactants, with no unexpected adverse events (96, 97). The recent FDA and EMA approval of canakinumab for patients with FMF resistant or intolerant to colchicine has been based on data from the CLUSTER trial (95).

A total of 63 patients with crFMF were randomized to receive canakinumab 150 mg or placebo every 4 weeks. At week 16, canakinumab compared with placebo produced a significantly higher response rate by day 15 (61 vs. 6%), higher rates of physician global assessment of disease activity (minimal/none) (65 vs. 9%), and higher C-reactive protein (CRP) levels ≤10 mg/L (68 vs. 6%) and serum amyloid A (SAA) levels ≤10 mg/L (65 vs. 9%) (95). Canakinumab also demonstrated a rapid and sustained disease control assessed with the Autoinflammatory Disease Activity Index (AIDAI) over 16 weeks, and approximately half of crFMF patients had inactive disease after the same period (164).

In the open-label phase from weeks 16–40, all FMF patients with a previous complete response to canakinumab 150 mg every 4 weeks maintained the absence of flares with canakinumab 150 mg every 8 weeks. After that period, the same dose interval of every 8 weeks was sufficient to maintain disease control in 53% of patients. An increase in the dose to 300 mg every 4 weeks was required by 8% of TRAPS patients (95).

Similarly to FMF patients of the CLUSTER study, TRAPS patients treated with canakinumab developed more frequently adverse events and serious adverse events than patients receiving placebo. The rate of infections was of 148 per 100 patient-years of treatment, and no serious infections were observed (95).

**Hyperimmunglobulin D Syndrome/Mevalonate Kinase Deficiency**

In HIDS/MKD, anakinra, and canakinumab may control or attenuate the intensity of attacks in most of patients. In the Eurofever Registry, among the 62 HIDS/MKD patients treated with anakinra, 84% obtained a positive response, which was complete in only 29% of them (15). On-demand administration of anakinra in HIDS/MKD patients decreases the duration and severity of symptoms attacks when started within 24 h after the onset of symptoms. However, on-demand regimen does not influence the frequency of attacks (84). Anakinra is recommended for treating HIDS/MKD patients with a level of evidence 2B and strength of recommendation C (14).

Efficacy and safety of canakinumab have been recently investigated in an open-label phase II study in nine patients (six pediatric and three adults) with HIDS, using a predefined dosage of 300 mg or 4 mg/kg for patients ≤40 kg (higher than the usual dose of 150 mg used in CAPS), with an interval administration of every 6 weeks (99). A significant reduction of attacks frequency and complete clinical response with normalization of inflammatory markers within the first month of treatment were noted in all patients (99).

As for crFMF and TRAPS, canakinumab has also been recently approved by the FDA and EMA for HIDS/MKD treatment, based on the data derived from the CLUSTER trial (95). Among the 72 HIDS/MKD patients included in the study (treated with
canakinumab 150 mg or placebo every 4 weeks), those receiving canakinumab experienced better response rate by day 15 (35 vs. 6%), higher rates of (minimal/none) physician global assessment of disease activity (46 vs. 6%), and higher CRP levels ≤10 mg/L (41 vs. 6%) and SAA levels ≤10 mg/L (41 vs. 6%) at week 16. Canakinumab was also associated with a rapid and sustained disease control assessed with AIDAI over 16 weeks, and 40% of HIDS/MKD patients had inactive disease after the same period (164). In the open-label phase from week 16–40, 82% of HIDS/MKD patients with a previous complete response to canakinumab 150 mg every 4 weeks maintained the absence of flares with canakinumab 150 mg every 8 weeks (95). After that period, the same dose interval of every 8 weeks maintained the disease controlled in only 23% of patients. An increase in the dose to 300 mg every 4 weeks was required by 29% of patients (95).

Similarly to FMF and TRAPS patients, in HIDS/MKD patients of the CLUSTER study, adverse events and serious adverse events were more frequent in patients treated with canakinumab than with placebo. Rates of infections and serious infections in HIDS/MKD were of 313.5 and 13.7 per 100 patient-years, respectively (164). Infections, such as pneumonia and gastroenteritis, occurred in ~25% of patients, but they did not require permanent discontinuation of treatment. Interestingly, an increase of anakinra dose was required in two cases during an infectious event with a concomitant disease flare (170).

Canakinumab induced clinical and biological remission in 75–90% of CAPS patients in the Eurofever Registry (15). The approval of canakinumab for CAPS was based on a 48-week, double-blind, placebo-controlled trial of 35 patients with CAPS (mainly MWS patients) treated with 150 mg every 8 weeks, in which 97% of patients had a complete response to canakinumab during the study period (102). In addition, another randomized controlled trial (103) and two observational studies on CAPS patients including all disease phenotypes similarly showed good results (100, 104).

A prospective study comparing the efficacy and safety of canakinumab and anakinra in 26 MWS patients concluded that both agents equally controlled disease activity and inflammatory markers and that canakinumab may be effective in some patients not responding to anakinra (104). Occasionally, patients receiving anakinra and those treated with canakinumab (mainly CINCA/NOMID patients) may require an increase of dose or frequency of administration of the drug (101, 104).

Rilonacept showed efficacy in 47 adult patients with CAPS (44 with FCAS and 3 with MWS) in a randomized controlled trial and in an extended open-label study of up to 96 weeks including 101 patients with favorable safety and tolerability profile in adult and pediatric patients (108, 109).

**PFAPA Syndrome**

Although genetic and pathogenic mechanisms of PFAPA syndrome are unknown, in a case report and a small cohort of five PFAPA patients resistant to glucocorticoids, the administration of anakinra has been effective in suppressing disease flares during the long-term follow-up (93, 94). Similarly, a pediatric case and an adult case of PFAPA syndrome have been reported to respond to canakinumab at a dose of 2 mg/kg and 150 mg every 8 weeks, respectively (105, 106).

**TNF Blockers**

Anti-TNF agents, mainly etanercept (a dimeric human TNF receptor p75-Fc fusion protein), infliximab (a chimeric monoclonal antibody against TNF-α), and adalimumab (a fully human monoclonal antibody against TNF-α), have been used in different monogenic autoinflammatory inflammasomopathies, generally with poorer efficacy than IL-1 blockers. These biologic agents have been approved for several autoimmune/inflammatory conditions. Etanercept has FDA and EMA indications for rheumatoid arthritis, juvenile
idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis; infliximab was approved by the FDA and EMA for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn disease, and ulcerative colitis, and adalimumab is indicated by the FDA and EMA for all the previous diseases (approved for etanercept and infliximab) plus non-infectious uveitis. In addition, the FDA approved adalimumab as therapy for hidradenitis suppurativa (acne inversa). None of the anti-TNF drugs have been approved by either the FDA or EMA for any of the monogenic autoinflammatory diseases.

**TNF Blockers in Autoinflammatory Diseases**

**Familial Mediterranean Fever**

In FMF, the experience with anti-TNF agents has been overall scarce and unclear. Two small series of 10 and 14 patients with crFMF and concomitant inflammatory conditions (chronic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis, or Crohn disease) treated with all the three TNF blockers resulted in good control of FMF and the associated disease (115, 116). Retrospective data included in the Eurofever Registry showed complete and partial response with etanercept (in seven and nine cases, respectively), infliximab (seven with complete and eight with partial response), and adalimumab (three with complete and two with partial response) (15). Similarly to the previous series, in this registry, anti-TNF agents seemed also to exert more benefit in cases with predominant arthritis (15). In a multicenter international retrospective study including 27 FMF patients treated with biologic agents, two patients received adalimumab and two etanercept as first agent. While one patient experienced a complete response, the remaining three had to discontinue the drug due to lack of efficacy after a mean duration of therapy of 9.3 months (117). The level of evidence of the efficacy of anti-TNF agents in crFMF, especially in those with articular involvement, is 3, but no grade of recommendation has been provided (13).

**Tumor Necrosis Factor Receptor–Associated Periodic Fever Syndrome**

In TRAPS, etanercept is the anti-TNF agent with the best reported results, because it has shown to prevent or reduce the intensity of attacks and the dose of glucocorticoids previously controlling disease activity (15, 117). However, it is relatively common that etanercept has to be discontinued because of lack of efficacy (15, 117), which has been reported after a period of 3.3 years (118). Although SHARE consensus recommends etanercept in some patients with a level of evidence 2B and grade of recommendation C, the experts also inform that the effect might decline over time (14).

In the Eurofever Registry, among 121 TRAPS patients treated with etanercept, 88% experienced a satisfactory response, which was complete in 26% of them (15). A multicenter international retrospective study including 47 TRAPS patients, 41 with pathogenic mutations and 6 with the R92Q variant, analyzed 20 and 4 patients treated with etanercept in each group, respectively. Among TRAPS caused by pathogenic mutations, ~50% of those receiving etanercept could achieve a complete clinical response. In addition, a total of 13 of 20 (65%) TRAPS patients discontinued anti-TNF, mostly due to a lack of efficacy. Compared to patients receiving anakinra, those treated with etanercept experienced less frequently a complete response and higher drug discontinuation rates (117). With regard to the four R92Q-TRAPS patients receiving etanercept as first-line therapy, only one (25%) had a complete response (117). Etanercept has also been reported effective in isolated TRAPS patients carrying the R92Q variant (57).

The use of infliximab and adalimumab has been associated with severe paradoxical reactions, and therefore, they are currently not recommended in TRAPS. While etanercept is a receptor fusion protein, infliximab, and adalimumab are TNF monoclonal antibodies. One of the proposed mechanisms by which infliximab is involved in a hyperinflammatory response is related to the failure in shedding infliximab-bound receptor from the cell surface, with the subsequent activation of antiapoptotic mechanisms and a widespread inflammatory response (171).

**Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency**

In HIDS/MKD, anti-TNF therapy can improve frequency and intensity of attacks. However, because anti–IL-1 agents can be considered the first-line therapy for HIDS/MKD patients (14, 95), TNF blockers are recommended as a second option (together with IL-6 blockade) in case of IL-1 blockers are ineffective or not tolerated, with a level of evidence 4 and grade of recommendation D (14).

In the Eurofever Registry, etanercept was the most frequently used anti-TNF drug, providing any improvement in 26 of 44 (59%) of HIDS/MKD patients, which was complete in seven (16%) of them (15). A multicenter retrospective study of eight HIDS/MKD patients treated with etanercept showed higher complete response rates (88%). However, etanercept was discontinued in four patients (50%) due to lack of efficacy (117).

**Cryopyrin-Associated Periodic Syndromes**

No evidence of efficacy of biological therapy (including anti-TNF agents) other than IL-1 blockade in CAPS patients is available (119).

**PFAPA Syndrome**

To date, no PFAPA cases treated with anti-TNF agents have been reported.

**Anti–IL-6 Agents: Tocilizumab**

Tocilizumab is a humanized monoclonal anti–IL-6 receptor antibody currently labeled by the FDA and EMA for rheumatoid arthritis, systemic and polyarticular juvenile idiopathic arthritis, giant cell arteritis and for the treatment of chimeric antigen receptor T cell–induced severe or life-threatening cytokine release syndrome. Tocilizumab has not been approved for any of the monogenic autoinflammatory diseases because the experience of its use, usually in patients unresponsive to other biologic agents, is still occasional.
**TABLE 3 |** Biological agents (other than IL-1 blockers), types of studies supporting the maximum evidence level, and response to treatment of the main monogenic autoinflammatory diseases (crFMF, TRAPS, HIDS/MKD, and CAPS)*.

| Drug                     | Disease               | Type of study | Response                                                                                       | References |
|--------------------------|-----------------------|---------------|------------------------------------------------------------------------------------------------|------------|
| Anti-TNF                 | crFMF                 | RCS           | Partial or complete response in few patients. Better efficacy in patients with articular involvement | (15, 115, 116) |
| Etanercept               | TRAPS**               | RCS           | Good response in 88% of patients, complete in 25–50% of them                                    | (15, 117, 118) |
| Infliximab               | HIDS/MKD              | RCS           | Good response in 59–88% of patients, complete in 16% of them. Lack of efficacy over time         | (15, 117)  |
| Adalimumab               | CAPS                  | CR            | No response                                                                                   | (119)      |
| Anti-IL-6                | crFMF                 | RCS, CS, CR   | Good response in patients resistant to colchicine, anti-IL-1, and anti-TNF agents               | (120–128) |
| Tocilizumab              | TRAPS                 | OR            | Good response in patients refractory to anti-TNF and anti-IL-1 agents                           | (129–131) |
|                           | HIDS/MKD              | OR            | Good response in patients refractory to anti-TNF and anti-IL-1 agents                           | (132–138) |
|                           | CAPS                  | OR            | No response                                                                                   | (119, 137) |
| JAK-inhibitors           | crFMF                 | CS            | Good response in patients refractory to anti-TNF, anti-IL-1, and anti-IL-6 agents               | (138–140) |
| Tofacitinib              |                       |               |                                                                                                 |            |

*No evidence about the use of these drugs in PFAPA syndrome.

**Infliximab and adalimumab are not recommended in TRAPS since their use has been associated with severe paradoxical reactions.

CAPS, cryopyrin-associated periodic syndromes; CR, case report; CS, case series; crFMF, colchicine-resistant familial Mediterranean fever; HIDS/MKD, hyperimmunoglobulin D and periodic fever syndrome/mevalonate kinase deficiency; IL, interleukin; JAK, Janus kinase; PFAPA, periodic fever with aphthous stomatitis, pharyngitis and cervical adenitis; RCS, retrospective cohort study; TNF, tumor necrosis factor; TRAPS, TNF-receptor associated periodic fever syndrome.

**Tocilizumab in Autoinflammatory Diseases**

**Familial Mediterranean Fever**

Tocilizumab has been successful in controlling disease activity in the majority of patients with crFMF reported as single cases, with good control of secondary amyloidosis in some of them (120–125). Tocilizumab effects over proteinuria in FMF-associated amyloidosis has been analyzed in two series of 11 and 12 patients resistant to colchicine, anti-IL-1, or anti-TNF agents, in whom the previous colchicine therapy was maintained (126, 127). Proteinuria improvement in any degree was achieved by 7 of 11 patients (64%) and 9 of 12 patients (75%), respectively (126, 127). In two of the responder patients, tocilizumab was discontinued, and proteinuria returned, with good control after restarting IL-6 blockade (128).

**Other Autoinflammatory Diseases**

Tocilizumab has been successfully used in three patients with TRAPS (129–131) and in seven HIDS/MKD cases (132–136) in whom anti-TNF and/or anti-IL-1 agents had previously failed. Negative results have been reported in two CAPS (CINCA/NOMID) patients treated with tocilizumab (119, 137). No evidence on the use of tocilizumab in PFAPA syndrome is currently reported.

**JAK Inhibitors**

JAK inhibition suppresses the constitutive phosphorylation of the transcription factor STAT-1, which blocks the induction of IFN-stimulated genes and subsequently leads to the regulation of the uncontrolled IFN production, causing inflammatory manifestations. Janus kinase inhibitors, such as tofacitinib, baricitinib, and ruxolitinib, are currently approved by the FDA and EMA for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis (tofacitinib), rheumatoid arthritis (baricitinib), and myelofibrosis and polycythemia vera (ruxolitinib, also approved for steroid-refractory acute graft-vs.-host disease by the FDA).

JAK inhibitors have demonstrated positive effects in several monogenic autoinflammatory diseases mediated by type I IFN (also named interferonopathies), including chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/proteasome-associated autoinflammatory syndrome, STING-associated vasculopathy with onset in infancy, familial chilblain lupus, and Aicardi–Goutières syndrome (172–175).

Because the pathogenic mechanism of the diseases included in this review consists mainly in the abnormal function of the inflammasome, as expected, the use of JAK inhibitors in monogenic inflammasomopathies remains anecdotal and limited to six crFMF patients previously failing to IL-1, TNF, and IL-6 blockers. However, interestingly, these cases were successfully treated with tofacitinib (138–140).

**Table 3** summarizes all the biological agents (other than IL-1 blockers) used in the main monogenic autoinflammatory diseases and PFAPA syndrome, and types of studies supporting the maximum evidence level for their use.

**PROPOSAL OF A PRACTICAL GUIDE FOR TREATING THE MAIN MONOGENIC AUTOINFLAMMATORY DISEASES AND PFAPA SYNDROME**

Based on the maximum level of evidence and grade of recommendation for FMF, CAPS, TRAPS, HIDS/MKD, and PFAPA syndrome, a proposed practical scheme for the treatment of these conditions is illustrated in **Figure 1**. Evidence-based recommendations for the treatment of the main monogenic autoinflammatory diseases have been...
extracted from previous consensus studies, such as the EULAR recommendations for the management of FMF (13) and the European SHARE recommendations for the management of TRAPS, HIDS/MKD, and CAPS (14).

Additional information used to generate levels of evidence has been incorporated mostly from results of new clinical trials, international multicenter registries, and retrospective data mainly from referral centers. According to the EULAR standard operating procedures for developing best practice to endorse recommendations, only the level of evidence is provided in those diseases with new therapeutic information but without recommendations issued by consensus expert opinion (11, 12).

The proposed therapeutic approach includes three different levels or situations: (a) first-line treatment (at the time of disease diagnosis or when symptomatic treatment used for milder situations is not effective); (b) milder cases or special clinical situations (including severe serositis or protracted febrile myalgia in case of FMF, or symptomatic treatment in milder presentations for the remaining conditions); and (c) second-line treatment (in case of patients not responding to first-line drugs or other biologic agents).

**STILL UNSOLVED AND OPEN QUESTIONS**

Despite the great efforts and progresses achieved during the last years in the treatment of monogenic autoinflammatory diseases, several questions remain still pending to be answered:

- how to define resistance or failure to any biologic drug?
- how to demonstrate the effect of biologic agents in preventing secondary amyloidosis?
- which is the right therapeutic window to initiate or switch to a biologic agent?
- which biological agent should be used as first?
- when it is time to switch to another biologic agent, and which biologic?
- how to identify the right moment to start on-demand treatment and when changing from continuous to on-demand administration is appropriate?
NEW TREATMENT STRATEGIES IN AUTOINFLAMMATORY DISEASES

It is of crucial importance to maintain and boost the international collaboration with patients’ registries for all the autoinflammatory diseases and also to promote initiatives that allow the generation of genetic, clinical, and therapeutic research. The latter should include drug development in preclinical (phases I and II) trials, whereas phase III trials (evaluating safety) should be now focused on testing new drugs and also on performing head-to-head comparisons between the current biologic agents, respectively.

With regard to preclinical trials, because the abnormal activation of the NLRP3 inflammasome seems to be implicated in conditions other than autoinflammatory diseases, such as diabetes, atherosclerosis, and cardiovascular and neurodegenerative diseases, several in vitro and in vivo studies are exploring the potential role of different pharmacological inhibitors of the NLRP3 inflammasome in NLRP3-associated diseases (176). While some of these new agents are small molecule inhibitors directly acting on the NLRP3 protein, others are targeting different components and products of the inflammasome. These new agents include glyburide, 16673-34-0, JC124, FC11A-2, parthenolide, VX-740, VX-765, Bay 11-7082, BHB, MNS, CY-09, OLT1177, oridonin, MCC950, and tranilast (176). Among them, tranilast and other small molecules, such as IZD174 and IZD334 (related to MCC950), are being used in patients with CAPS, in phases I and II clinical trials.

Currently, the efficacy and safety of alternative biologic drugs and small molecules are being studied or pending of results in several ongoing clinical trials, including:

1) Tocilizumab for the treatment of FMF—a randomized, double-blind, phase II proof-of-concept study (ClinicalTrials.gov identifier: NCT03446209). This trial will analyze the efficacy of tocilizumab in adult patients with crFMF, also failing to other biologic agents.

2) A randomized, double-blind, parallel-group comparison trial of tocilizumab for colchicine-resistant FMF (UMIN-CTR Clinical Trial ID: UMIN000028010). This (phase III) trial will analyze the efficacy of tocilizumab in patients from 12 to 75 years with crFMF (177).

3) An open-label continuation trial of tocilizumab for FMF with colchicine ineffective or intolerance (UMIN-CTR Clinical Trial ID: UMIN000032557). This trial is expected to obtain evidence regarding the long-term safety of tocilizumab in crFMF patients (178).

4) Safety and tolerability, pharmacokinetic, and pharmacodynamic study with IZD334 (ClinicalTrials.gov identifier: NCT04086602). This is the first-in-human, single-center, double-blind, randomized, crossover (phase I) study of IZD334 (a small molecule inhibitor of the NLRP3 inflammasome) conducted in healthy adults as well as an open-label cohort in adult patients with CAPS.

5) Safety and tolerability, pharmacokinetic, and pharmacodynamic study with inzomelid (ClinicalTrials.gov identifier: NCT04015076). A phase I, randomized, double-blind, placebo-controlled, single- and multiple-ascending-dose study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of inzomelid (or IZD174, a small molecule inhibitor of the NLRP3 inflammasome) in healthy adult participants, as well as an open-label cohort to confirm the safety, pharmacokinetics, and pharmacodynamics of inzomelid in adult patients with CAPS.

6) A clinical study of tranilast in the treatment of CAPS (ClinicalTrials.gov identifier: NCT03923140). A single-arm prospective cohort (phase II) study designed to observe the efficacy and safety of tranilast (a small molecule inhibitor of the NLRP3 inflammasome) in CAPS patients.

7) Ilaris® (canakinumab) in PFAPA patients (ClinicalTrials.gov identifier: NCT02775994). This single-arm open-label pilot study will analyze the efficacy of canakinumab during the first 2 months of treatment in 10 children with PFAPA syndrome experiencing frequent flares.

CONCLUDING REMARKS

- Colchicine, used at therapeutic doses, is the criterion-standard treatment for FMF and of some help in PFAPA patients, mostly in those carrying heterozygous MEFV gene mutations.
- NSAIDs improve symptoms in most patients with any autoinflammatory disease, but they are usually insufficient to control symptoms and do not influence the underlying cause of the disease in any of them.
- Glucocorticoids, generally used at medium or high doses, may be effective when administered on demand (in short courses) in most of the monogenic conditions. In some TRAPS patients, continuous administration of glucocorticoids may be also useful. Anyway, because most patients will require a biologic agent to control the disease activity, glucocorticoids may be reserved as initial treatment to prove response or may be also administered in a continuous or on-demand modality for mild/non-severe cases. Glucocorticoids have demonstrated special utility in FMF patients experiencing protracted febrile myalgia and severe serositis (in a short course at high doses) and in PFAPA patients (in a single high-dose administration), representing the treatment of choice in PFAPA syndrome.
- Among biologic agents, IL-1 blockers are the most relevant and useful drugs in the treatment of the main monogenic autoinflammatory diseases, especially in those considered inflammasomopathies.
- Anakinra and canakinumab have FDA and EMA approval as first-line treatment for CAPS patients, whereas rilonacept has been approved only by the FDA. Both anakinra and canakinumab are of clear utility in crFMF, TRAPS, and HIDS/MKD patients, and canakinumab has been recently approved by the FDA and EMA for these three conditions. Anakinra has been used with success on demand in patients experiencing frequent flares.
REFERENCES

1. Federici S, Sormani MP, Özen S, Lachmann HJ, Amaryan G, Woo P, et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. *Ann Rheum Dis.* (2015) 74:799–805. doi: 10.1136/annrheumdis-2014-206580

2. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-bet. *Mol Cell.* (2002) 10:417–26. doi: 10.1016/S1097-2765(02)00599-3

3. Soriano A, Pras E. Familial Mediterranean fever: genetic update. *1st Med Assoc J.* (2014) 16:274–6.

4. Özen S, Bilginer Y. A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. *Nat Rev Rheumatol.* (2013) 10:135–47. doi: 10.1038/nrrheum.2013.174

5. Aksentijevich I, Zhou Q. NF-kB pathway in autoinflammatory diseases: dysregulation of protein modifications by ubiquitin defines a new category of autoinflammatory diseases. *Front Immunol.* (2017) 8:399. doi: 10.3389/fimmu.2017.00399

6. de Jesus AA, Goldbach-Mansky R. Newly recognized mendelian disorders with rheumatic manifestations. *Curr Opin Rheumatol.* (2015) 27:511–9. doi: 10.1097/BOR.0000000000000207

7. Lee-Kirsch MA. The type i interferonopathies. *Ann Rev Med.* (2017) 68:297–315. doi: 10.1146/annurev-med-050715-104506

8. Sun SC. Non-canonical NF-kappaB signaling pathway. *Cell Res.* (2011) 21:71–85. doi: 10.1038/cr.2010.177

9. Manthiram K, Zhou Q, Aksentijevich I, Kastner DL. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. *Nat Immunol.* (2017) 18:832–42. doi: 10.1038/nri.3777

10. Cattalini M, Solani M, Lopalco G, Rigante D, Cantarini L. Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists’ lens. *Intern Emerg Med.* (2016) 11:78–91. doi: 10.1007/s11739-016-1466-y

11. Dougados M, Betteridge N, Burmester GR, Fuller-Ziegler L, Guillenin F, Hirvonen J, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. *Ann Rheum Dis.* (2004) 63:1172–6. doi: 10.1136/ard.2004.023697

12. van der Heijde D, Aletaha D, Carmona L, Edwards CJ, Kvien TK, Kouloumas M, et al. Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. *Ann Rheum Dis.* (2015) 74:8–13. doi: 10.1136/annrheumdis-2014-206530

13. Özen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. *Ann Rheum Dis.* (2016) 75:644–51. doi: 10.1136/annrheumdis-2015-208690

14. Ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, et al. Recommendations for the management of autoinflammatory diseases. *Ann Rheum Dis.* (2015) 74:1636–44. doi: 10.1136/annrheumdis-2015-207546

15. Ter Haar N, Lachmann H, Özen S, Woo P, Uziel Y, Modesto C, et al. Treatment of autoinflammatory diseases: results from the eurofever registry and a literature review. *Ann Rheum Dis.* (2013) 72:678–85. doi: 10.1136/annrheumdis-2011-201288

16. Malkinson FD. Colchicine. new uses of an old, old drug. *Arch Dermatol.* (1982) 118:453–7. doi: 10.1001/archderm.118.7.453

17. Ben-Chetrit E, Levy M. Familial Mediterranean fever. *Lancet.* (1998) 351:659–64. doi: 10.1016/S0140-6736(97)90408-7

18. Ben-Chetrit E, Levy M. Colchicine: 1998 update. *Semin Arthritis Rheum.* (1998) 28:48–59. doi: 10.1016/S0049-0172(98)80028-0

19. Cocco G, Chu DC, Pandolfi S. Colchicine in clinical medicine. a guide for internists. *Eur J Intern Med.* (2010) 21:503–8. doi: 10.1016/j.ejim.2010.09.010

20. Goldfinger SE. Colchicine for familial Mediterranean fever. *N Engl J Med.* (1972) 287:1302. doi: 10.1056/NEJM197212112872514

21. Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW. Colchicine therapy for familial Mediterranean fever: a double-blind trial. *N Engl J Med.* (1974) 291:934–7. doi: 10.1056/NEJM197410312911804

22. Zemer D, Revach M, Pras M, Modan B, Schor S, Sohar E, et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean Fever. *N Engl J Med.* (1974) 291:932–4. doi: 10.1056/NEJM197410312911803

23. Zemer D, Pras M, Sohar E, Modan B, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean Fever. *N Engl J Med.* (1986) 314:1001–5. doi: 10.1056/NEJM198604173141601

24. FDA Alert. Information for Healthcare Professionals: New Safety Information for Colchicine (marketed as Colcrys). (2009). Available online at: https://www.fda.gov/drugs/drugsafety/ postmarketdrugssafetyinformationforpatientsandproviders/ucm174382h.htm

25. Kershnenobich D, Rojkind M, Quiroga A, Alcocer-Varela J. Effect of colchicine on lymphocyte and monocyte function and its relation to fibroblast proliferation in primary biliary cirrhosis. *Hepatology.* (1990) 11:205–9. doi: 10.1002/hep.1840110208

26. Sackett DL, Varma JK. Molecular mechanism of colchicine action: induced local unfolding of beta-tubulin. *Biochemistry.* (1995) 32:13560–5. doi: 10.1021/bi02122a023

27. Vandevelde A, Martin SR, Engberghs Y. Response of microtubules to the addition of colchicine and tubulin-colchicine: evaluation of models for the interaction of drugs with microtubules. *Biochem J.* (1997) 323:189–96. doi: 10.1042/bj3230189
66. Seyahi E, Ozdogan H, Celik S, Ugraylur S, Yazici H. Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. *Clin Exp Rheumatol*. (2006) 24:599–103.

67. Drenth JP, vonk AG, Simon A, Powell R, van der Meer JW. Lack of efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial. *J Pharmacol Exp Ther*. (2001) 298:1221–6.

68. Sahlezhadeh F, Jahangiri S, Mohammadi E. Dapsonse as an alternative therapy in children with familial Mediterranean fever. *Iran J Pediatr*. (2012) 22:23–7.

69. Calguner M, Apras S, Ozbalkan Z, Ozturk MA, Erentli I, Kiraz S. The efficacy of continuous interferon alpha administration as an adjunctive agent to colchicine-resistant familial Mediterranean fever patients. *Clin Exp Rheumatol*. (2004) 22:541–4.

70. Tunkurt E, Tunca M, Akbaylar H, Gonen O. Resolving familial Mediterranean fever attacks with interferon alpha. *Br J Rheumatol*. (1996) 35:1188–9. doi: 10.1093/rheumatology/35.11.1188

71. Tweezer-Zaks N, Rabinovich E, Lidar M, Livneh A. Interferon-alpha as a treatment modality for colchicine-resistant familial Mediterranean fever. *J Rheumatol*. (2008) 35:1362–5.

72. Vandecasteele SJ, De Paepe P, De Vriese AS. Successful treatment of renal AA amyloidosis in familial Mediterranean fever with pegylated alpha-2a interferon. *Clin Nephrol*. (2011) 75(Suppl. 1):1–3. doi: 10.5141/CN106447

73. Tunca M, Akar S, Soyturt M, Kirkali G, Resmi H, Akhunlar H, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: a double-blind, placebo-controlled trial. *J Exp Rheumatol*. (2004) 22:544–5.

74. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. *Nat Rev Drug Discov*. (2012) 11:633–52. doi: 10.1038/nrd3800

75. Liao Z, Grimshaw RS, Rosenstein DI. Identification of a specific interleukin 1 inhibitor in the urine of febrile patients. *J Exp Med*. (1984) 159:126–36. doi: 10.1084/jem.159.1.126

76. Balavoine JF, de Rochemonteix B, Williamson K, Seckinger P, Cruaud A, Dayer JM. Prostaglandin E2 and collagenase production by fibroblasts in vivo and in vitro. *Immunol Today*. (1991) 12:404–10.

77. Brik R, Butbul-Aviel Y, Lubin S, Ben Dayan E, Rachmilewitz-Minei T, Tseng Tran TA, Bader-Meunier B, et al. Two-year results from an open-label, single-arm pilot study of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome (TRAPS) with or without AA amyloidosis. *Ann Rheum Dis*. (2011) 70:1431–6. doi: 10.1136/annrheumdis-2010-200726

78. Akar S, Cetin P, Kalyoncu U, Karadag O, Sari I, Cinar M, et al. Nationwide experience with off-label use of interleukin-1 targeting treatment in familial Mediterranean fever patients. *Arthritis Care Res*. (2018) 70:1090–4. doi: 10.1002/art.39346

79. Obici L, Meini A, Cattalini M, Chicca S, Galliani M, Donadei S, et al. Favouroable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. *Ann Rheum Dis*. (2011) 70:1511–2. doi: 10.1136/annrheumdis-2010-201438

80. Gattorno M, Obici L, Cattalini M, Tormey V, Abrams K, Davis N, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. *Ann Rheum Dis*. (2017) 76:173–8. doi: 10.1136/annrheumdis-2015-209031

81. Akar S, Tuncu M, Akaylar H, Gonen O. Resolving familial Mediterranean fever attacks with interferon alpha. *Br J Rheumatol*. (1996) 35:1188–9. doi: 10.1093/rheumatology/35.11.1188

82. Tweezer-Zaks N, Rabinovich E, Lidar M, Livneh A. Interferon-alpha as a treatment modality for colchicine-resistant familial Mediterranean fever. *J Rheumatol*. (2008) 35:1362–5.

83. Vandecasteele SJ, De Paepe P, De Vriese AS. Successful treatment of renal AA amyloidosis in familial Mediterranean fever with pegylated alpha-2a interferon. *Clin Nephrol*. (2011) 75(Suppl. 1):1–3. doi: 10.5141/CN106447

84. Balavoine JF, de Rochemonteix B, Williamson K, Seckinger P, Cruaud A, Dayer JM. Prostaglandin E2 and collagenase production by fibroblasts in vivo and in vitro. *Immunol Today*. (1991) 12:404–10.
syndrome is driven by the phenotype severity rather than the age. *Arthritis Res Ther.* (2013) 15:R33. doi: 10.1186/ar4184

102. Lachmann HJ, Kone-Paut I, Kuenemmer-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. *N Engl J Med.* (2009) 360:2416–25. doi: 10.1056/NEJMoa0810787

103. Kone-Paut I, Lachmann HJ, Kuenemmer-Deschner JB, Hachulla E, Leslie KS, Mouy R, et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. *Arthritis Res Ther.* (2013) 15:R64. doi: 10.1186/ar4237

104. Scoiyo A, Yildiz G, Torun Bayram M, Kavukcu S. IL-1beta blockade in periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome: case-based review. *Rheumatol Int.* (2019). doi: 10.1007/s00292-019-04389-3. [Epub ahead of print].

105. Lopalco G, Spalding SJ, Giannini EH, Huang B, Johnson A, Park ES, et al. Canakinumab in adolescents with systemic-onset juvenile idiopathic arthritis and PFAPA syndrome. *Arthritis Rheum.* (2017) 34:2091–103. doi: 10.1007/s10024-017-0074-x

106. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh AF, et al. Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. *Arthritis Rheum.* (2012) 64:908–13. doi: 10.1002/art.33416

107. Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park ES, et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopyrin-associated periodic syndromes: results of a 72-week open-label extension study. *Clin Ther.* (2012) 34:3001–103. doi: 10.1016/j.clinthera.2012.09.009

108. Soriano A, Verecchia E, Afeletra A, Landolfi R, Manna R, Il-1beta biological treatment of familial Mediterranean fever. *Clin Rev Allergy Immunol.* (2013) 45:117–30. doi: 10.1007/s12016-013-8358-y

109. Soriano A, Bardin C, Bader-Meunier B, Mouy R, Compeyrot-Lacassagne S, Foissac E, et al. Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. *BMJ Pharmacol Toxicol.* (2013) 14:40. doi: 10.1186/2050-6511-14-40

110. Kim DC, Reitz B, Carmichael DE, Bloedow DC. Kidney as a major clearance organ for recombinant human interleukin-1 receptor antagonist. *J Pharm Sci.* (1995) 84:575–80. doi: 10.1002/jps.2600804513

111. Yang BX, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. *Clin Pharmacol Ther.* (2003) 73:845–94. doi: 10.1016/S0002-9265(03)00094-8

112. Goshen I, Kreisel T, Ounallah-Saad H, Renbaum P, Zalzstein Y, Ben-Hur T, et al. A dual role for interleukin-1 in hippocampal-dependent memory processes. *Psychoneuroendocrinology.* (2007) 32:1106–15. doi: 10.1016/j.psyneuen.2007.09.004

113. Bilgen SA, Kilic I, Akdogan A, Kiraz S, Kalyoncu U, Karadag O, et al. Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. *J Clin Rheumatol.* (2011) 17:358–62. doi: 10.1097/RHU.0b013e3182682f5

114. Ozgocmen S, Akgul O. Anti-TNF agents in familial mediterranean fever: report of three cases and review of the literature. *Mod Rheumatol.* (2011) 21:684–90. doi: 10.3109/10165-011-0463-2

115. Ozen S, Kuenemmer-Deschner JB, Cinmaz R, Livneh A, Quartier P, Kone-Paut I, et al. International retrospective chart review of treatment patterns in severe FMF, TRAPS and MKD/HIDS. *Arthritis Care Res.* (2017) 69:578–86. doi: 10.1002/aac.32102

116. Bulua AC, Mogul DB, Aksentijevich I, Singh H, He DY, Muenz LR, et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. *Arthritis Rheum.* (2012) 64:908–13. doi: 10.1002/art.33416
136. Rafiq NK, Lachmann H, Joensen F, Herlin T, Brogan PA. Tocilizumab for the treatment of mevalonate kinase deficiency. *Case Rep Pediatr*. (2018) 2018:3514645. doi: 10.1155/2018/3514645
137. Snegireva LS, Kostik MM, Caroli F, Ceccherini I, Gattorno M, Chasnky VG. Failure of tocilizumab treatment in a CINCA patient: clinical and pathogenic implications. *Rheumatology*. (2013) 52:1731–2. doi: 10.1093/rheumatology/ket121
138. Gok K, Cengiz G, Erol K, Ozogcmen S. Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever. *Acta Reumatol Port*. (2017) 42:88–90.
139. Garcia-Robledo JE, Aragon CC, Nieto-Aristizabal I, Posso-Osorio I, Canas CA, Tobon GJ. Tofacitinib for familial Mediterranean fever: a new alternative therapy? *Rheumatology* (2019) 58:553–4. doi: 10.1093/rheumatology/key384
140. Karadeniz H, Guler AA, Atas N, Satis H, Salman RB, Babaoglu H, et al. Contribution of IL-1 to resistance to Streptococcus pneumoniae infection arthritis: results from the British Society for Rheumatology Biologics. *The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: retrospective analysis of efficacy and safety*. *Ann Rheum Dis*. (2019) 78:1072–9. doi: 10.1136/annrheumdis-2018-215682
141. Fleischmann RM, Schechtman J, Dietrich T, Brandt J, Handel ML, Burmester GR, et al. On-demand treatment with anakinra for patients with well-controlled end-stage renal disease (ESRD). *J Clin Pharm Ther*. (2010) 35:173–9. doi: 10.1111/j.1399-8715.2010.01482.x
142. Mitroulis I, Skendros P, Oikonomou A, Tzioufas AG, Ritis K. The efficacy of anakinra: a treatment option for selected TRAPS patients. *Ann Rheum Dis*. (2015) 74:1714–9. doi: 10.1136/annrheumdis-2013-204877
143. Chasnyk VG. Failure of tocilizumab treatment in a CINCA patient: central nervous system inflammation. *Arthritis Rheumatol*. (2017) 69:1325–36.
144. Yokoyama K, Ikeya M, Umeda K, Oda H, Nodomi S, Nasu A, et al. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of RESURGE, a phase III, international safety study. *Rheumatology*. (2014) 41:1703–11. doi: 10.3893/rheum.1311226
145. van der Hilst J, Moutschen M, Messiaen PE, Lauwersy BR, Vanderschueren S. Improvement of disease activity in patients with colchicine-resistant familial Mediterranean fever and long-standing destructive arthritis. *Ann Rheum Dis*. (2011) 70:1347–8. doi: 10.1136/ard.2010.146878
146. Kone-Paut I, Piram M, Benseler S, Hofer M, Lachmann H, Hoffman HM, et al. Improvement of disease activity in patients with colchicine-resistant FMF, HDIS/KD and TRAPS assessed by autoinflammatory disease activity index (AIAID); results from the cluster trial. *Ann Rheum Dis*. (2017) 76 (Suppl. 2):398–9. doi: 10.1136/annrheumdis-2017-eular.5655
147. Grimwood C, Despert V, Jeru I, Hentgen V. On-demand treatment with anakinra: a treatment option for selected TRAPS patients. *Rheumatology*. (2014) 53:1744–51. doi: 10.1093/rheumatology/ket111
148. Almeida MQ, Tsang KM, Cheadle C, Watkins T, Grivel JC, Nesterova M, et al. Protein kinase a regulates caspase-1 via Ets-1 in bone marrow-derived cell-derived lesions: a link between cyclic AMP and pro-inflammatory pathways in osteoblast progenitors. *Hum Mol Genet*. (2011) 20:165–75. doi: 10.1093/hmg/ddq455
149. Yokoyama K, Ikeya M, Umeda K, Oda H, Nodomi S, Nasu A, et al. Enhanced chondrogenesis of induced pluripotent stem cells from patients with neonatal-onset multisystem inflammatory disease occurs via the caspase-1-independent cAMP/protein kinase A/CREB pathway. *Arthritis Rheumatol*. (2015) 67:302–14. doi: 10.1002/art.38912
150. Galea J, Ogungbenro K, Hulme S, Greenhalgh A, Arons L, Scarlett S, et al. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. *J Cerel Blood Flow Metab*. (2011) 31:439–47. doi: 10.1038/jcbfm.2010.103
151. Ahmadi N, Brewer CC, Zalewski C, King KA, Butman JA, Plass N, et al. Tofacitinib for familial Mediterranean fever in children and adolescents. *Rheumatology*. (2017) 56:2102–8. doi: 10.1093/rheumatology/kew208
171. Nedjai B, Quillinan N, Coughlan RJ, Church L, McDermott MF, Hitman GA, et al. Lessons from anti-TNF biologics: infliximab failure in a TRAPS family with the T50M mutation in TNFRSF1A. Adv Exp Med Biol. (2011) 691:409–19. doi: 10.1007/978-1-4419-6612-4_43

172. Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. (2018) 128:3041–52. doi: 10.1172/JCI98814

173. Wenzel J, van Holt N, Maier J, Vonnahme M, Bieber T, Wolf D. JAK1/2 Inhibitor ruxolitinib controls a case of chilblain lupus erythematosus. J Invest Dermatol. (2016) 136:1281–3. doi: 10.1016/j.jid.2016.02.015

174. Konig N, Fiehn C, Wolf C, Schuster M, Cura Costa E, Tungler V, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. (2017) 76:468–72. doi: 10.1136/annrheumdis-2016-209841

175. Crow YJ, Vanderver A, Orcesi S, Kuijpers TW, Rice GI. Therapies in aicardi-goutieres syndrome. Clin Exp Immunol. (2014) 175:1–8. doi: 10.1111/cei.12115

176. Zahid A, Li B, Kombe AJK, Jin T, Tao J. Pharmacological inhibitors of the NLRP3 inflammasome. Front Immunol. (2019) 10:2538. doi: 10.3389/fimmu.2019.02538

177. Koga T, Sato S, Miyamoto J, Hagimori N, Kawazoe Y, Arinaga K, et al. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial. Trials. (2018) 19:715. doi: 10.1186/s13063-018-3105-6

178. Koga T, Hagimori N, Sato S, Morimoto S, Hosogaya N, Fukushima C, et al. An open-label continuation trial of tocilizumab for familial mediterranean fever with colchicine ineffective or intolerance: Study protocol for investigator-initiated, multicenter, open-label trial. Medicine. (2020) 99:e18328. doi: 10.1097/MD.0000000000018328

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Soriano, Soriano, Espinosa, Manna, Emmi, Cantarini and Hernández-Rodríguez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.